UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 69

Sortiert nach

Antiretroviral therapy: current drugs

Infectious disease clinics of North America, 2014-09, Vol.28 (3), p.371

2014

Volltextzugriff (PDF)

Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Updated Guidelines From the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America

Clinical infectious diseases, 2014-05, Vol.58 (9), p.1308-1311

2014

Volltextzugriff (PDF)

Analysis of Site Heterogeneity and HIV Outcomes Across Rural and Urban Study Sites in Phidisa II - A Multi-site Randomized Controlled Antiretroviral Treatment Trial in a South African Military Cohort

Current HIV research, 2017-01, Vol.15 (3), p.178

2017

Volltextzugriff (PDF)

Dramatic improvement of MRI abnormalities of HIV encephalopathy after suppressive antiretroviral therapy

AIDS (London), 2023-07, Vol.37 (8), p.1339-1340

2023

Volltextzugriff (PDF)

Iatrogenic Cushing Syndrome after Epidural Triamcinolone Injections in an HIV Type 1–Infected Patient Receiving Therapy with Ritonavir-Lopinavir

Clinical infectious diseases, 2008-12, Vol.47 (12), p.e97-e99

2008

Volltextzugriff (PDF)

Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel

Annals of internal medicine, 2021-01, Vol.174 (1), p.93

2021

Volltextzugriff (PDF)

Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine

Clinical infectious diseases, 2018-07, Vol.67 (2), p.193-201

2018

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Tolerability of Once-Daily Darunavir With Cobicistat and Weekly Isoniazid/Rifapentine

Journal of acquired immune deficiency syndromes (1999), 2023-12, Vol.94 (5), p.468

2023

Volltextzugriff (PDF)

Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank

Clinical infectious diseases, 2023-12, Vol.77 (12), p.1635-1643

2023

Volltextzugriff (PDF)

Eight-day Inpatient Directly Observed Therapy for Antiretroviral Therapy (ART) Failure: A Tool For Preventing Unnecessary ART Changes and Optimizing Adherence Support

Clinical infectious diseases, 2020-03, Vol.70 (6), p.1222-1225

2020

Volltextzugriff (PDF)

Utilization of Direct Oral Anticoagulants in People Living with Human Immunodeficiency Virus: Observational Data from the District of Columbia Cohort

Clinical infectious diseases, 2020-12, Vol.71 (10), p.e604-e613

2020

Volltextzugriff (PDF)

Ex vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV

EBioMedicine, 2024-06, Vol.104, p.105151, Article 105151

2024

Volltextzugriff (PDF)

Efavirenz but Not Atazanavir/Ritonavir Significantly Reduces Atovaquone Concentrations in HIV-Infected Subjects

Clinical infectious diseases, 2016-04, Vol.62 (8), p.1036-1042

2016

Volltextzugriff (PDF)

Early Presence of HIV-1 Subtype C in Washington, D.C

AIDS research and human retroviruses, 2018-08, Vol.34 (8), p.680

2018

Volltextzugriff (PDF)

Decreased Absorption of Dolutegravir and Tenofovir Disoproxil Fumarate, But Not Emtricitabine, in an HIV‐Infected Patient Following Oral and Jejunostomy‐Tube Administration

Pharmacotherapy, 2017-08, Vol.37 (8), p.e82-e89

2017

Volltextzugriff (PDF)

GRL-142 binds to and impairs HIV-1 integrase nuclear localization signal and potently suppresses highly INSTI-resistant HIV-1 variants

Science advances, 2023-07, Vol.9 (28), p.eadg2955

2023

Volltextzugriff (PDF)

The pharmacist: An indispensable partner in HIV care

American journal of health-system pharmacy, 2016-04, Vol.73 (7), p.431-431

2016

Volltextzugriff (PDF)

Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient

Antiviral therapy, 2011-01, Vol.16 (2), p.257-261

2011

Volltextzugriff (PDF)

Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone

Journal of acquired immune deficiency syndromes (1999), 2013-07, Vol.63 (3), p.355

2013

Volltextzugriff (PDF)

Rapid Development of High-Level Resistance to Dolutegravir With Emergence of T97A Mutation in 2 Treatment-Experienced Individuals With Baseline Partial Sensitivity to Dolutegravir

Open forum infectious diseases, 2018-10, Vol.5 (10), p.ofy221

2018

Volltextzugriff (PDF)

Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy

Antiviral therapy, 2016-01, Vol.21 (6), p.553-558

2016

Volltextzugriff (PDF)

Plasma Pharmacokinetics of Sulfadiazine Administered Twice Daily versus Four Times Daily Are Similar in Human Immunodeficiency Virus-Infected Patients

Antimicrobial Agents and Chemotherapy, 2004-02, Vol.48 (2), p.635-637

2004

Volltextzugriff (PDF)

Impaired Maraviroc and Raltegravir Clearance in a Human Immunodeficiency Virus–Infected Patient with End‐Stage Liver Disease and Renal Impairment: A Management Dilemma

Pharmacotherapy, 2012-01, Vol.32 (1), p.e1-e6

2012

Volltextzugriff (PDF)

Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa

Journal of acquired immune deficiency syndromes (1999), 2011-11, Vol.58 (3), p.304

2011

Volltextzugriff (PDF)

Lack of Effect from a Previous Single Dose of Nevirapine on Virologic and Immunologic Responses After 6 Months of Antiretroviral Regimens Containing Either Efavirenz or Lopinavir-Ritonavir

Pharmacotherapy, 2011-02, Vol.31 (2), p.158-163

2011

Volltextzugriff (PDF)

1 – 25 von 69

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(54)

Publikationsform

Sprache

Englisch
(69)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Antiretroviral therapy: current drugs

Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Updated Guidelines From the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America

Analysis of Site Heterogeneity and HIV Outcomes Across Rural and Urban Study Sites in Phidisa II - A Multi-site Randomized Controlled Antiretroviral Treatment Trial in a South African Military Cohort

Dramatic improvement of MRI abnormalities of HIV encephalopathy after suppressive antiretroviral therapy

Iatrogenic Cushing Syndrome after Epidural Triamcinolone Injections in an HIV Type 1–Infected Patient Receiving Therapy with Ritonavir-Lopinavir

Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel

Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine

Pharmacokinetics, Safety, and Tolerability of Once-Daily Darunavir With Cobicistat and Weekly Isoniazid/Rifapentine

Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank

Eight-day Inpatient Directly Observed Therapy for Antiretroviral Therapy (ART) Failure: A Tool For Preventing Unnecessary ART Changes and Optimizing Adherence Support

Utilization of Direct Oral Anticoagulants in People Living with Human Immunodeficiency Virus: Observational Data from the District of Columbia Cohort

Ex vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV

Efavirenz but Not Atazanavir/Ritonavir Significantly Reduces Atovaquone Concentrations in HIV-Infected Subjects

Early Presence of HIV-1 Subtype C in Washington, D.C

Decreased Absorption of Dolutegravir and Tenofovir Disoproxil Fumarate, But Not Emtricitabine, in an HIV‐Infected Patient Following Oral and Jejunostomy‐Tube Administration

GRL-142 binds to and impairs HIV-1 integrase nuclear localization signal and potently suppresses highly INSTI-resistant HIV-1 variants

The pharmacist: An indispensable partner in HIV care

Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient

Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone

Rapid Development of High-Level Resistance to Dolutegravir With Emergence of T97A Mutation in 2 Treatment-Experienced Individuals With Baseline Partial Sensitivity to Dolutegravir

Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy

Plasma Pharmacokinetics of Sulfadiazine Administered Twice Daily versus Four Times Daily Are Similar in Human Immunodeficiency Virus-Infected Patients

Impaired Maraviroc and Raltegravir Clearance in a Human Immunodeficiency Virus–Infected Patient with End‐Stage Liver Disease and Renal Impairment: A Management Dilemma

Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa

Lack of Effect from a Previous Single Dose of Nevirapine on Virologic and Immunologic Responses After 6 Months of Antiretroviral Regimens Containing Either Efavirenz or Lopinavir-Ritonavir

Suchergebnisse filtern